Josa-Laorden C, Sola A, Giménez-López I, Rubio-Gracia J, Garcés-Horna V, Pérez-Calvo J I
Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, España; Departamento de Medicina Interna, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
Departamento de Nefrología experimental, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.
Rev Clin Esp (Barc). 2018 Jun-Jul;218(5):232-240. doi: 10.1016/j.rce.2018.03.009. Epub 2018 Apr 16.
Worsening renal function is associated with an adverse prognosis for patients with acute heart failure (AHF). Urea-creatinine ratio (U:C ratio) might be useful for measuring renal function and could help stratify patients with AHF.
An observational and prospective study was conducted to analyse the prognostic value of the U:C ratio, measured during the first 24-28 hours of admission, for patients hospitalised for decompensated Heart failure, and its relationship with estimated glomerular filtration rate (eGFR) and acute kidney injury (AKI).
The study included 204 patients, with a mean age of 79.3 years, and a median eGFR of 55 mL/min/1.73m. In the multivariate analysis, an U:C ratio above the median (50) was related to the development of AKI (36.5% vs. 21.9%) and to increased mortality, both overall (OR 2.75) and by HF (OR 3.50) in long term. In combination with eGFR, the U:C ratio showed prognostic value in patients with normal eGFR (mortality of 4.4% for an U:C ratio ≤ 50 vs. 22% for U:C ratio > 50; p=0.01), as well as a better predictive capacity for AKI than each of them separately (AUC, 0.718; 95% CI 0.643-0.793; p>.000).
An U:C ratio > 50 is a predictor of increased long-term mortality for patients hospitalised for decompensated HF and with normal eGFR. Given the simplicity of this biomarker, its use in clinical practice should be more systematic.
肾功能恶化与急性心力衰竭(AHF)患者的不良预后相关。尿素-肌酐比值(U:C比值)可能有助于评估肾功能,并可用于对AHF患者进行分层。
进行了一项观察性前瞻性研究,分析入院后最初24 - 28小时测得的U:C比值对失代偿性心力衰竭住院患者的预后价值,及其与估计肾小球滤过率(eGFR)和急性肾损伤(AKI)的关系。
该研究纳入了204例患者,平均年龄79.3岁,eGFR中位数为55 mL/min/1.73m²。在多变量分析中,U:C比值高于中位数(50)与AKI的发生相关(36.5%对21.9%),并且与长期总体死亡率增加(OR 2.75)以及因心力衰竭导致的死亡率增加(OR 3.50)相关。与eGFR联合使用时,U:C比值在eGFR正常的患者中显示出预后价值(U:C比值≤50时死亡率为4.4%,U:C比值>50时为22%;p = 0.01),并且对AKI的预测能力优于单独使用eGFR或U:C比值(AUC,0.718;95% CI 0.643 - 0.793;p <.000)。
U:C比值>50是失代偿性心力衰竭住院且eGFR正常患者长期死亡率增加的预测指标。鉴于这种生物标志物的简便性,其在临床实践中的应用应更加系统化。